Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

RVPH

Reviva Pharmaceuticals Holdings Inc

Dec 11 • 04:00PM ET

2.82

Dollar change +0.30
Percentage change 11.71	%

Healthcare • Biotechnology • USA • NASD

Peers: ACAD BPMC CYTK LGND AVDL MDGL IRWD PTGX KNSA OVID

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.11	Insider Own	14.79%	Shs Outstand	33.44M	Perf Week	125.20%
Market Cap	94.13M	Forward P/E	-	EPS next Y	-0.83	Insider Trans	0.00%	Shs Float	28.50M	Perf Month	181.50%
Income	-33.38M	PEG	-	EPS next Q	-0.23	Inst Own	30.47%	Short Float	21.62%	Perf Quarter	151.34%
Sales	0.00M	P/S	-	EPS this Y	38.79%	Inst Trans	252.02%	Short Ratio	6.35	Perf Half Y	86.42%
Book/sh	-0.30	P/B	-	EPS next Y	17.49%	ROA	-512.93%	Short Interest	6.16M	Perf Year	-26.50%
Cash/sh	0.17	P/C	16.93	EPS next 5Y	-	ROE	-1806.28%	52W Range	0.60 - 5.67	Perf YTD	-45.34%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-50.35%	Beta	-0.10
Dividend TTM	-	Quick Ratio	0.39	Sales past 5Y	0.00%	Gross Margin	-	52W Low	369.17%	ATR (14)	0.38
Dividend Ex-Date	-	Current Ratio	0.39	EPS Y/Y TTM	34.56%	Oper. Margin	-	RSI (14)	86.87	Volatility	46.09% 21.98%
Employees	15	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.67	Target Price	15.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	43.30%	Payout	-	Rel Volume	6.02	Prev Close	2.52
Sales Surprise	-	EPS Surprise	-2.46%	Sales Q/Q	-	Earnings	Nov 14 AMC	Avg Volume	969.83K	Price	2.82
SMA20	97.37%	SMA50	121.32%	SMA200	59.03%	Trades		Volume	5,834,840	Change	11.71%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-20-23	Initiated	ROTH MKM	Buy	$12
Jun-08-23	Initiated	The Benchmark Company	Speculative Buy	$17
Jan-24-22	Initiated	H.C. Wainwright	Buy	$10

Nov-14-24 05:25PM	Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -7.02%
Nov-12-24 08:00AM	Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia (GlobeNewswire) +32.00%
Nov-06-24 08:00AM	Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024 (GlobeNewswire)
Oct-31-24 08:00AM	Reviva to Participate in the UBS Global Healthcare Conference (GlobeNewswire)
Oct-08-24 08:00AM	Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
08:30AM	Loading…
Oct-02-24 08:30AM	Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire) -9.86%
Sep-26-24 08:30AM	Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference (GlobeNewswire)
Sep-09-24 08:00AM	Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia (GlobeNewswire)
Sep-04-24 08:00AM	Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-27-24 08:00AM	Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024 (GlobeNewswire)
Aug-21-24 06:00AM	Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -25.65%
Aug-14-24 08:00AM	Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-06-24 08:00AM	Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jul-09-24 08:00AM	Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension (GlobeNewswire)
May-29-24 04:45PM	Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
08:00AM	Loading…
May-28-24 08:00AM	Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.80%
May-21-24 08:00AM	Reviva to Participate in the BIO International Convention (GlobeNewswire) -15.26%
May-15-24 08:00AM	Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia (GlobeNewswire) -6.30%
May-14-24 01:53PM	RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace) +7.35%
08:00AM	Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-13-24 08:00AM	Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference (GlobeNewswire) -9.09%
May-09-24 08:00AM	Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting (GlobeNewswire) -24.11%
Apr-15-24 08:30AM	Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia (GlobeNewswire) -5.69%
08:05AM	Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-28-24 08:00AM	Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting (GlobeNewswire)
Mar-26-24 08:00AM	Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting (GlobeNewswire) +21.97%
Mar-11-24 08:00AM	Reviva to Present at the UBS Virtual CNS Day (GlobeNewswire) -5.14%
Mar-07-24 08:00AM	Reviva to Present at the 36th Annual ROTH Conference (GlobeNewswire)
Feb-20-24 08:00AM	Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire)
Feb-06-24 08:00AM	Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia (GlobeNewswire)
08:00AM	Loading…
Jan-25-24 08:00AM	Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference (GlobeNewswire)
Jan-10-24 08:00AM	Reviva to Present at Webull LIVE! Healthcare Webinar on January 17 (ACCESSWIRE)
Jan-04-24 08:00AM	Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones (GlobeNewswire)
Dec-15-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Dec-12-23 01:02PM	Life Science Investor Forum Agenda Announced for December 14th, 2023 (GlobeNewswire)
Dec-11-23 08:35AM	Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum (GlobeNewswire)
Nov-30-23 04:05PM	Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference (GlobeNewswire)
Nov-20-23 04:05PM	Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +5.94%
Nov-16-23 08:00AM	Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -8.50%
Nov-14-23 05:23PM	Reviva Pharmaceuticals Holdings Inc Reports Q3 2023 Financial Results (GuruFocus.com) -9.19% -8.84%
04:01PM	Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-01-23 05:30AM	RVPH: RECOVER Topline (Zacks) -8.42%
Oct-30-23 07:54AM	UPDATE 1-Reviva Pharma's schizophrenia drug succeeds in late-stage study (Reuters) +46.40%
07:37AM	Reviva Pharma's schizophrenia drug succeeds in late-stage study (Reuters)
07:30AM	Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia (GlobeNewswire)
Sep-29-23 09:00AM	Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV (ACCESSWIRE)
Sep-25-23 06:00AM	Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia (GlobeNewswire)
Sep-22-23 01:30PM	Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV (ACCESSWIRE)
Sep-07-23 06:00AM	Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-18-23 06:40AM	RVPH: RECOVER Enrollment Complete (Zacks)
Aug-17-23 06:00AM	Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia (GlobeNewswire)
Aug-14-23 04:01PM	Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-02-23 12:45PM	RedChip Launches 'Small Stocks, Big Money' Podcast (ACCESSWIRE) -5.85%
Jul-31-23 08:00AM	Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August (GlobeNewswire)
Jun-26-23 06:00AM	Reviva Pharmaceuticals to be Added to Russell Microcap® Index (GlobeNewswire)
Jun-22-23 06:00AM	Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia (GlobeNewswire)
Jun-15-23 06:00AM	Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in June (GlobeNewswire)
May-25-23 06:00AM	Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives (GlobeNewswire) -12.79%
May-22-23 06:30AM	Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting (GlobeNewswire)
May-19-23 06:30AM	Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform (GlobeNewswire)
May-18-23 06:30AM	Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023 (GlobeNewswire) -5.39%
May-17-23 05:41AM	RVPH: Psoriasis IND Expected (Zacks Small Cap Research)
May-15-23 04:05PM	Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +8.86%
May-12-23 06:30AM	Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference (GlobeNewswire) -7.32%
May-11-23 06:30AM	Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data (GlobeNewswire) -6.71%
May-04-23 06:00AM	Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023 (GlobeNewswire) +7.56%
May-01-23 04:01PM	Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives (GlobeNewswire) +8.32%
Apr-25-23 07:00AM	Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia (GlobeNewswire)
Apr-20-23 04:05PM	Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry (GlobeNewswire) +7.94% +5.33%
Apr-19-23 09:00AM	Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE)
Apr-04-23 06:02AM	RVPH: RECOVER Parallel Studies Complete (Zacks Small Cap Research)
Mar-30-23 07:30AM	Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -10.09%
Mar-10-23 04:50AM	RVPH: Brilaroxazine Enthusiasm Abounds (Zacks Small Cap Research) -5.06%
Mar-07-23 08:00AM	Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference (GlobeNewswire)
Jan-31-23 07:09AM	We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate (Simply Wall St.) +9.93%
06:00AM	Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference (GlobeNewswire)
Jan-25-23 08:00AM	RedChip CEO Dave Gentry Invited to Join Forbes Business Council (ACCESSWIRE)
Jan-04-23 06:00AM	Reviva Pharmaceuticals Announces Letter to Shareholders (GlobeNewswire)
Dec-16-22 05:25AM	As Reviva Pharmaceuticals Holdings, Inc.'s (NASDAQ:RVPH) market cap increased US$11m, insiders who bought last year may be reflecting on buying more (Simply Wall St.) -8.76%
Dec-15-22 09:05AM	Reviva Pharmaceuticals' Schizophrenia Candidate Shows Favorable Drug-Drug Interaction Data (Benzinga)
06:00AM	Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine (GlobeNewswire)
Nov-21-22 06:00AM	Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208 (GlobeNewswire)
Nov-17-22 05:10AM	RVPH: Enthusiasm Abounds with Brilaroxazine (Zacks Small Cap Research)
Nov-14-22 04:05PM	Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -20.44%
Nov-05-22 09:42AM	Reviva Pharmaceuticals Holdings, Inc.'s (NASDAQ:RVPH) largest shareholders are individual investors who were rewarded as market cap surged US$25m last week (Simply Wall St.)
Oct-31-22 08:00AM	Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia (GlobeNewswire)
Oct-13-22 06:00AM	Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE) +16.12%
Sep-26-22 06:00AM	Reviva Pharmaceuticals to Present at the Lytham Partners Fall 2022 Investor Conference (GlobeNewswire)
Sep-07-22 08:02AM	Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-06-22 08:30AM	Reviva Pharmaceuticals Holdings, Inc. Announces $8.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -14.66%
Aug-31-22 06:25PM	The 5 Bestand 5 WorstNasdaq Stocks in August (Barrons.com) -12.75%
Aug-24-22 07:07AM	Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely (Simply Wall St.) +6.04%
Aug-19-22 06:02AM	RVPH: 20% of the Way There (Zacks Small Cap Research)
Aug-15-22 04:15PM	Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) +15.49% -11.56%
Jul-27-22 07:15AM	Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline (GlobeNewswire)
Jul-02-22 08:21AM	Chief Financial Officer Narayan Prabhu Just Bought A Handful Of Shares In Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (Simply Wall St.)
Jun-24-22 08:35AM	Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing (GlobeNewswire)
Jun-21-22 04:21PM	UPDATE - Life Sciences Investor Forum: Company Executives Present Live June 23rd (GlobeNewswire)
Jun-17-22 08:00AM	Reviva Pharmaceuticals to Present at Upcoming June Investor Conferences (GlobeNewswire)
Jun-02-22 06:00AM	Reviva Pharmaceuticals to Participate in the 2022 BIO International Convention (GlobeNewswire)

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RVPH

Reviva Pharmaceuticals Holdings Inc

Upgrade your FINVIZ experience